US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ASTRAZENECA PLC ADRhedged

53.28

0.0000

Volume:- -

Turnover:- -

Market Cap:1.60M

PE:- -

High:53.28

Open:53.28

Low:53.28

Close:53.28

52wk High:56.90

52wk Low:48.44

Shares:30.00K

Float Shares:10.00K

Volume Ratio:- -

T/O Rate:- -

Dividend:0.58

Dividend Rate:1.08%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Amgen Stock Forecast: AMGN Reclaims $410 as Pipeline Catalysts Build

AstraZeneca's Asthma Maintenance Treatment Gets EU Approval

MT Newswires Live

European Pharma Leaders Push for National Reforms to Boost Investment

AstraZeneca PLC Stock Rises Monday, Outperforms Market

European Equities Traded in the US as American depositary Receipts Rise in Monday Trading

MT Newswires Live

AstraZeneca's Alexion Gets Positive EU Recommendation for Klygefa in Rare Muscle Disease

MT Newswires Live

AstraZeneca, Daiichi Sankyo's Enhertu Recommended for EU Approval for HER2 Positive Breast Cancer

MT Newswires Live

AstraZeneca’s BLA for efzimfotase alfa accepted, granted Priority Review by FDA

AstraZeneca Wins FDA Priority Review for Rare Bone Disease Drug

MT Newswires Live

AstraZeneca Advances Thursday, Outperforms Market

AstraZeneca, Daiichi Breast-Cancer Drug Gets Nod in England After U.S. Pharma Deal

AstraZeneca PLC Stock Falls Wednesday, Underperforms Market

The 'CIA' Strategy Beating the Market: How One Top-Performing Money Manager Spots Mispriced Stocks.

AstraZeneca's Long-Term Outlook Could Look Safer After Next Year

AstraZeneca Can Meet 2030 Target Even if Lung-Cancer Trial Fails

Guardant Health Could Benefit From AstraZeneca Trial Failure, UBS Says

MT Newswires Live

AstraZeneca price target lowered to 150 GBp from 160 GBp at Berenberg

Berenberg Trims Price Target on AstraZeneca to $203 From $214, Keeps Buy Rating

MT Newswires Live

AstraZeneca's Portfolio Diversity Bodes Well

Berenberg Bank Remains a Buy on AstraZeneca (AZN)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/AZNH/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AZNH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AZNH\",,,,,undefined,":{"symbol":"AZNH","market":"US","secType":"STK","nameCN":"ASTRAZENECA PLC ADRhedged","latestPrice":53.2774,"timestamp":1790798400000,"preClose":53.2774,"halted":3,"volume":0,"delay":0,"changeRate":0,"floatShares":10000,"shares":30000,"eps":0,"marketStatus":"Halted","change":0,"latestTime":"09-30 16:00:00 EDT","open":53.2774,"high":53.2774,"low":53.2774,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1790841600000},"marketStatusCode":0,"adr":0,"exchange":"NYSE","adjPreClose":53.2774,"dividendRate":0.010836,"bidAskSpread":0,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AZNH\",,,,,undefined,":{"symbol":"AZNH","floatShares":10000,"roa":"--","roe":"--","lyrEps":0,"shares":30000,"dividePrice":0.57729,"high":53.2774,"amplitude":0,"preClose":53.2774,"low":53.2774,"week52Low":48.44,"pbRate":"--","week52High":56.8955,"institutionHeld":0,"latestPrice":53.2774,"eps":0,"divideRate":0.010836,"volume":0,"delay":0,"ttmEps":0,"open":53.2774,"prevYearClose":54.226,"prevWeekClose":53.2774,"prevMonthClose":53.2774,"prevQuarterClose":53.2774,"fiveDayClose":53.2774,"twentyDayClose":53.2774,"sixtyDayClose":53.2774},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AZNH\",params:#limit:5,,,undefined,":[{"date":"2025-12-16","symbol":"AZNH","amount":0.57729,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"ASTRAZENECA PLC ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-24"},{"date":"2024-12-16","symbol":"AZNH","amount":2.71402,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-16","defaultRemindTime":1734359400000,"name":"ASTRAZENECA PLC ADRhedged","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-23","payableDate":"2024-12-16","currency":"USD","dateTimestamp":1734325200000,"payDate":"2024-12-23"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AZNH\",market:\"US\",,,undefined,":[{"executeDate":"2024-12-16","recordDate":"2024-12-16","paymentDate":"2024-12-23","value":2.71402,"currency":"USD"},{"executeDate":"2025-12-16","recordDate":"2025-12-16","paymentDate":"2025-12-24","value":0.57729,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AZNH\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AZNH\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2669646482","title":"Amgen Stock Forecast: AMGN Reclaims $410 as Pipeline Catalysts Build","url":"https://stock-news.laohu8.com/highlight/detail?id=2669646482","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669646482?lang=en_us&edition=fundamental","pubTime":"2026-09-23 23:00","pubTimestamp":1790175600,"startTime":"0","endTime":"0","summary":"Amgen rebounds to $410.24 as dazodalibep and IMDELLTRA strengthen the pipeline while $418.73 becomes the next technical test.\n","market":"us","thumbnail":"https://resource.tradingkey.com/uploads/20260923/AMGEN-82b57eea98fd4d6fa458e68c35b3ab95.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/uploads/20260923/AMGEN-82b57eea98fd4d6fa458e68c35b3ab95.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/analysis/stocks/us-stocks/262182585-stocks-amgen-stock-forecast-pipeline-410-breakout-tradingkey","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSLP","TEST","07766","IBB","07366","LU1061106388.HKD","LU0868494617.USD","PFS","LU1571399168.USD","TSLT","TSII","TSLG","TBXU","BK7095","BGSX","TESC","IE0002141913.USD","PBE","TLA","ORR.AU","LU2468319806.SGD","09366","TSDD","IE0009355771.USD","LU1983299246.USD","AZNH","TSLO","TSLZ","CRSH","TSYY","AMGN","TSLI","LU2237443549.SGD","PJP","09766","BIB","TESL","AZN","TSL","TSLQ","TSLW","TSLY","TSLR","TSLS","BBH","ORR","IBBQ","TSLL","LU2242652126.USD","ELOL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669106449","title":"AstraZeneca's Asthma Maintenance Treatment Gets EU Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2669106449","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669106449?lang=en_us&edition=fundamental","pubTime":"2026-09-23 16:14","pubTimestamp":1790151271,"startTime":"0","endTime":"0","summary":"AstraZeneca  has received approval for the single-inhaler Trixeo Aerosphere in the European Union as a maintenance treatment for asthma in certain patients aged at least 12 years, the company said Wednesday.The approval covers patients who are not adequately controlled by a combination of a medium dose inhaled corticosteroid and long-acting beta2-agonist, according to the company.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0432979614.USD","LU2237443549.SGD","AZN","LU2089984988.USD","BK4585","LU0708994859.HKD","BK4588","BK4007","LU2237443895.HKD","LU0889565916.HKD","IE00B3T34201.USD","LU2237443382.USD","LU0109394709.USD","LU2417539215.USD","LU2237443978.SGD","LU2237443622.USD","LU0128525929.USD","AZNH","LU1267930573.SGD","BK4568","LU2468319806.SGD","LU0029864427.USD","LU2237443465.HKD","LU0310800379.SGD","LU2456880835.USD","LU0289739699.SGD","LU0320765992.SGD","LU1829250122.USD","LU2462157665.USD","LU0058720904.USD","LU2236285917.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669140420","title":"European Pharma Leaders Push for National Reforms to Boost Investment","url":"https://stock-news.laohu8.com/highlight/detail?id=2669140420","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669140420?lang=en_us&edition=fundamental","pubTime":"2026-09-22 22:14","pubTimestamp":1790086440,"startTime":"0","endTime":"0","summary":"Several drugmakers urged European authorities to increase health budgets and speed up approvals for new medicines, warning the region is losing out to the U.S. and China in the race to attract investm","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GSKH","LU2237443382.USD","IE00B4R5TH58.HKD","BK4578","LU0432979614.USD","LU1093756168.USD","LU2237443895.HKD","LU0889565916.HKD","IE00BKVL7J92.USD","BK4599","LU0320765992.SGD","LU2468319806.SGD","LU0211331839.USD","LU0708994859.HKD","LU0058720904.USD","AZN","LU2237443622.USD","BK4532","HRTS","IE00BJJMRZ35.SGD","LU0029864427.USD","NVS","LU0310800379.SGD","IE0009355771.USD","NVOH","CANC","LU0154236417.USD","LU1267930573.SGD","NVOC","IE00B2B36J28.USD","LU2089984988.USD","BK4007","IE00BJT1NW94.SGD","SNY","LU0070302665.USD","LU2237443978.SGD","MEDX","GSK.UK","THNR","RHHBY","GSK","BK4568","IE0002141913.USD","LU2237443465.HKD","LU2237443549.SGD","NVOX","IE00BFXG1179.USD","AZNH","IE00B3T34201.USD","BK4588","03165","LU2456880835.USD","BK4585","LU2236285917.USD","LU0289739699.SGD","IE00BFTCPJ56.SGD","LU0109394709.USD","IE00BZ1G4Q59.USD","LU0128525929.USD","LU0208291251.USD","LU1829250122.USD","LU0320765489.SGD","LU1093756325.SGD","LU2417539215.USD","OZEM","PPH","NVO","LU2462157665.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669164723","title":"AstraZeneca PLC Stock Rises Monday, Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2669164723","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669164723?lang=en_us&edition=fundamental","pubTime":"2026-09-22 00:00","pubTimestamp":1790006400,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of AstraZeneca PLC advanced 0.4% to SEK1,645.50 Monday on what proved to be an overall favorable trading session for the stock market, with the OMX Nordic 40 Index rising 0.1% to 2,657.68.This was the stock's third consecutive day of gains.The company closed SEK280.00 below its 52-week high of SEK1,925.50, which the company achieved on April 10, 2026.Trading volume was 394,017, compared to the 50-day average trading volume of 620,487.Data source: Dow Jones Market Data, FactSet","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU2237443978.SGD","LU2237443622.USD","BK4588","LU2236285917.USD","LU2237443549.SGD","LU1267930573.SGD","LU1829250122.USD","LU2462157665.USD","LU0432979614.USD","LU2237443382.USD","LU2456880835.USD","IE00B3T34201.USD","LU2237443465.HKD","LU0889565916.HKD","LU0320765992.SGD","LU0310800379.SGD","LU0058720904.USD","LU0109394709.USD","LU0128525929.USD","AZN","LU0029864427.USD","BK4568","LU2468319806.SGD","LU0289739699.SGD","LU0708994859.HKD","LU2237443895.HKD","BK4007","AZNH","LU2089984988.USD","LU2417539215.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669616164","title":"European Equities Traded in the US as American depositary Receipts Rise in Monday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2669616164","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669616164?lang=en_us&edition=fundamental","pubTime":"2026-09-21 23:29","pubTimestamp":1790004548,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts started the week higher on Monday, rising 0.45% to 1,928.13 on the S&P Europe Select ADR Index.From continental Europe, the gainers from biotech firm BioNTech  and Banco Santander , which advanced 2.1% and 1.7% respectively. They were followed by lenders Banco Bilbao Vizcaya Argentaria  and ING , which increased 1.5% and 1.3% respectively.The decliners from continental Europe were led by pharmaceutical firm Novo Nordisk  and accommodations booking site trivago , which dropped 8% and 3.8% respectively. They were followed by petroleum refiner Equinor  and biopharmaceutical company Cellectis , which lost 2.7% and 1.3% respectively.The gainers from the UK were led by Akari Therapeutics  and software firm Endava , which rose 4% and 3.6%, respectively. They were followed by pharmaceutical companies GSK  and AstraZeneca , which were up 1.5% and 1.2% respectively.The decliners from the UK and Ireland were led by oil and gas com","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0300736492.USD","BK4551","LU0084288595.USD","CLLS","LU0320765646.SGD","LU2468319806.SGD","LU2089984988.USD","BK4521","LU2237443895.HKD","LU1829250122.USD","GSKH","LU2462157665.USD","LU0278409577.USD","LU1162221912.USD","BK4007","BK4201","AZNH","BK4207","IE00B3T34201.USD","BBVA","BPH","BK4535","ING","LU2417539215.USD","PPH","LU2237443382.USD","IE00BKVL7J92.USD","BP","BK4588","LU1267930573.SGD","LU1093756325.SGD","LU0320765992.SGD","BK4599","LU2237443549.SGD","GSIB","LU2456880835.USD","BDRX","LU0648005311.SGD","BK4134","LU2237443978.SGD","OZEM","LU0162691827.USD","AZN","NVOX","LU0154236417.USD","LU0289739699.SGD","LU0109394709.USD","SHEH","LU0098860793.USD","BHP","BK4568","GSK","NVO","THNR","IE00BZ1G4Q59.USD","AKTX","LU0058720904.USD","BK4168","LU0432979614.USD","SAN","LU0006061336.USD","LU0029864427.USD","BK4077","SLX","BK4548","LU2237443465.HKD","NVOC","LU0708994859.HKD","TRVG","BK4139","LU1093756168.USD","GSK.UK","NVOH","DAVA","LU0310800379.SGD","COAL","EQNR","LU0300736062.USD","BNTX","BK4585","BK4532","LU2237443622.USD","LU0889565916.HKD","SHEL","LU0128525929.USD","LU2236285917.USD","LU0072461881.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668921895","title":"AstraZeneca's Alexion Gets Positive EU Recommendation for Klygefa in Rare Muscle Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2668921895","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668921895?lang=en_us&edition=fundamental","pubTime":"2026-09-18 22:03","pubTimestamp":1789740232,"startTime":"0","endTime":"0","summary":"AstraZeneca  said Friday that Alexion, AstraZeneca Rare Disease's Klygefa received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use recommending approval in the European Union.Klygefa is intended to treat adults with generalized myasthenia gravis, a rare autoimmune disorder characterized by reduced muscle function and severe muscle weakness.The opinion was supported by data from the phase 3 PREVAIL trial, which the company said demonstrated the efficacy and safety profile of the long-acting C5 complement inhibitor in patients with the disease.Price: 166.82, Change: +0.68, Percent Change: +0.41","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AZNH","LU0889565916.HKD","BK4568","LU2468319806.SGD","LU2236285917.USD","LU0029864427.USD","LU2456880835.USD","LU2089984988.USD","AZN","LU1829250122.USD","LU2237443978.SGD","BK4588","LU2237443382.USD","LU0320765992.SGD","LU2237443622.USD","BK4585","LU0432979614.USD","LU2237443549.SGD","LU0109394709.USD","LU0128525929.USD","LU0708994859.HKD","LU2237443465.HKD","LU0310800379.SGD","BK4007","LU0058720904.USD","LU0289739699.SGD","LU2237443895.HKD","LU1267930573.SGD","IE00B3T34201.USD","LU2462157665.USD","LU2417539215.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668987925","title":"AstraZeneca, Daiichi Sankyo's Enhertu Recommended for EU Approval for HER2 Positive Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2668987925","media":"MT Newswires Live","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668987925?lang=en_us&edition=fundamental","pubTime":"2026-09-18 20:37","pubTimestamp":1789735074,"startTime":"0","endTime":"0","summary":"AstraZeneca  and Daiichi Sankyo's Enhertu has been recommended for approval in the European Union as a monotherapy for the adjuvant treatment of adults with resected HER2 positive breast cancer who have residual disease after neoadjuvant treatment, Daiichi Sankyo said Friday.The European Medicines Agency's Committee for Medicinal Products for Human Use based its recommendation on results from a phase 3 trial that showed Enhertu significantly reduced the risk of invasive disease recurrence or death by 53%, Daiichi Sankyo said.The European Commission will now review the recommendation to determine marketing authorization in the EU, the company added.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0889565916.HKD","LU0432979614.USD","LU0058720904.USD","LU2456880835.USD","LU1829250122.USD","LU0320765992.SGD","LU0109394709.USD","LU2237443978.SGD","LU2237443382.USD","AZN","LU0128525929.USD","LU0310800379.SGD","LU1267930573.SGD","LU2237443549.SGD","LU2468319806.SGD","LU2237443895.HKD","LU2089984988.USD","LU2236285917.USD","BK4007","LU0289739699.SGD","BK4568","EPV","LU0708994859.HKD","AZNH","BK4588","LU2237443465.HKD","BK4585","IE00B3T34201.USD","LU2237443622.USD","LU2417539215.USD","LU0029864427.USD","LU2462157665.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668705947","title":"AstraZeneca’s BLA for efzimfotase alfa accepted, granted Priority Review by FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2668705947","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668705947?lang=en_us&edition=fundamental","pubTime":"2026-09-18 18:35","pubTimestamp":1789727735,"startTime":"0","endTime":"0","summary":"Alexion, AstraZeneca’s (AZN) Rare Disease’s Biologics License Application, BLA, for efzimfotase alfa has been accepted and granted Priority Review ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/astrazenecas-bla-for-efzimfotase-alfa-accepted-granted-priority-review-by-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/astrazenecas-bla-for-efzimfotase-alfa-accepted-granted-priority-review-by-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2237443895.HKD","LU0889565916.HKD","LU0708994859.HKD","BK4588","LABU","LU2462157665.USD","BK4568","LU2237443549.SGD","LU2237443978.SGD","LU0310800379.SGD","LU2237443382.USD","LU2237443465.HKD","AZNH","LU1829250122.USD","LU0029864427.USD","LU2237443622.USD","LU0128525929.USD","LU2236285917.USD","LU1267930573.SGD","BK4007","LU2089984988.USD","LU0058720904.USD","LU2456880835.USD","AZN","LU0320765992.SGD","LU2468319806.SGD","IE00B3T34201.USD","LU0289739699.SGD","BK4585","LU0109394709.USD","LU2417539215.USD","LU0432979614.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668794506","title":"AstraZeneca Wins FDA Priority Review for Rare Bone Disease Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2668794506","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668794506?lang=en_us&edition=fundamental","pubTime":"2026-09-18 15:51","pubTimestamp":1789717864,"startTime":"0","endTime":"0","summary":"AstraZeneca  said Friday the US Food and Drug Administration granted priority review to its Alexion unit's biologics license application for efzimfotase alfa to treat patients aged two years and older with hypophosphatasia, a genetic bone disorder.The health regulator is expected to make a regulatory decision in H1 2027, and the filing is supported by results from three phase 3 trials in children and adults, the company said.The proposed biweekly treatment is designed to address skeletal abnormalities and functional issues associated with the disorder, AstraZeneca said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2456880835.USD","LU0889565916.HKD","LU0128525929.USD","LU2468319806.SGD","LU0310800379.SGD","LU0320765992.SGD","LU0708994859.HKD","AZNH","LU2237443382.USD","BK4585","LU1829250122.USD","LU0432979614.USD","LU2237443549.SGD","LU0289739699.SGD","LU2237443895.HKD","LU2236285917.USD","LU2089984988.USD","LU0029864427.USD","LU0058720904.USD","LU2237443622.USD","LU2237443978.SGD","LU0109394709.USD","LU2417539215.USD","BK4007","BK4568","LU2462157665.USD","LABU","LU2237443465.HKD","BK4588","IE00B3T34201.USD","AZN","LU1267930573.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668996972","title":"AstraZeneca Advances Thursday, Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2668996972","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668996972?lang=en_us&edition=fundamental","pubTime":"2026-09-18 00:07","pubTimestamp":1789661220,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.AstraZeneca PLC  shares rose 2.41% to GBP124.28 Thursday, on what proved to be an all-around favorable ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1829250122.USD","LU2456880835.USD","LU2237443622.USD","LU2417539215.USD","LU0708994859.HKD","LU0109394709.USD","AZN","LU2089984988.USD","LU2237443382.USD","LU2236285917.USD","LU2462157665.USD","LU1267930573.SGD","LU2468319806.SGD","LU2237443549.SGD","BK4007","BK4588","LU0058720904.USD","LU0310800379.SGD","AZNH","LU0289739699.SGD","LU0432979614.USD","LU0889565916.HKD","IE00B3T34201.USD","LU0320765992.SGD","LU0128525929.USD","LU0029864427.USD","BK4585","BK4568","LU2237443465.HKD","LU2237443895.HKD","LU2237443978.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668959487","title":"AstraZeneca, Daiichi Breast-Cancer Drug Gets Nod in England After U.S. Pharma Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2668959487","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668959487?lang=en_us&edition=fundamental","pubTime":"2026-09-17 14:08","pubTimestamp":1789625280,"startTime":"0","endTime":"0","summary":"AstraZeneca and Daiichi Sankyo's breast-cancer drug Enhertu won approval from the drug-cost watchdog for routine use in England, after the regulator changed its recommendation following the U.S.-U.K. pharmaceutical-pricing deal.The National Institute for Health and Care Excellence said Thursday that it would recommend Enhertu for routine use on England's National Health Service, which means around 1,000 patients annually with an advanced form of breast cancer can now be offered the treatment.An independent NICE committee had previously rejected the drug at the price proposed by the companies. The parties reached an agreement after the regulator's methods changed due to the U.S.-U.K. pharma deal, NICE said.AstraZeneca's U.K. president Tom Keith-Roach said the green light in England brings access to the medicine into line with Scotland and 26 other European countries.NICE said it had made 25 other breast-cancer treatments available on the NHS since 2018, but that Enhertu for this group o","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","LU0058720904.USD","LU2236285917.USD","LU0109394709.USD","LU0289739699.SGD","DSNKY","LU0889565916.HKD","LU2237443978.SGD","LU2237443465.HKD","LU2462157665.USD","LU1267930573.SGD","LU2089984988.USD","BK4007","LU0029864427.USD","IE00B3T34201.USD","LU2468319806.SGD","AZN","LU0708994859.HKD","LU2237443895.HKD","BK4585","LU0128525929.USD","LU1829250122.USD","LU2237443382.USD","LU2417539215.USD","LU0310800379.SGD","BK4588","LU0320765992.SGD","LU2456880835.USD","LU2237443549.SGD","AZNH","LU2237443622.USD","LU0432979614.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668982507","title":"AstraZeneca PLC Stock Falls Wednesday, Underperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2668982507","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668982507?lang=en_us&edition=fundamental","pubTime":"2026-09-17 00:00","pubTimestamp":1789574400,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of AstraZeneca PLC dropped 0.1% to SEK1,593.00 Wednesday on what proved to be an overall favorable trading session for the stock market, with the OMX Nordic 40 Index rising 0.6% to 2,630.58.The stock's fall  snapped a two-day winning streak.The company closed SEK332.50 short of its 52-week high of SEK1,925.50, which the company reached on April 10, 2026.Trading volume was 606,290, compared to the 50-day average trading volume of 634,192.Data source: Dow Jones Market Data, FactSet","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0432979614.USD","LU2237443549.SGD","AZN","LU2089984988.USD","BK4585","LU0708994859.HKD","BK4588","BK4007","LU2237443895.HKD","LU0889565916.HKD","IE00B3T34201.USD","LU2237443382.USD","LU0109394709.USD","LU2417539215.USD","LU2237443978.SGD","LU2237443622.USD","LU0128525929.USD","AZNH","LU1267930573.SGD","BK4568","LU2468319806.SGD","LU0029864427.USD","LU2237443465.HKD","LU0310800379.SGD","LU2456880835.USD","LU0289739699.SGD","LU0320765992.SGD","LU1829250122.USD","LU2462157665.USD","LU0058720904.USD","LU2236285917.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667600950","title":"The 'CIA' Strategy Beating the Market: How One Top-Performing Money Manager Spots Mispriced Stocks.","url":"https://stock-news.laohu8.com/highlight/detail?id=2667600950","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667600950?lang=en_us&edition=fundamental","pubTime":"2026-09-16 19:20","pubTimestamp":1789557600,"startTime":"0","endTime":"0","summary":"T. Rowe Price manager looks for trouble to find his global value betsT.Rowe Price manager Sebastien Mallet is betting on more than technology for his five-star fund.One secret to global value manager Sebastien Mallet's success?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1699723380.USD","LU0048584097.USD","LU0823434583.USD","LU0823434740.USD","SKDD","LU1267930490.SGD","BIB","BK4142","LU2324357040.USD","JPM","IE00B1BXHZ80.USD","BK4581","IE00BQXX3D17.EUR","LU1430594728.SGD","SG9999004303.SGD","SIL","IE00B5TLWC47.USD","LU0353189763.USD","LU0109392836.USD","LU0964807845.USD","LU1861220033.SGD","LU2552382215.SGD","BK4573","LU1839511570.USD","IE00BKDWB100.SGD","BK4588","LU0859254822.USD","LU0320765646.SGD","LU2357627491.SGD","AMDS","WUGI","LU0612318971.USD","LU0210536198.USD","LU2106854487.HKD","GAMR","BK4007","LU0211331839.USD","UYG","LU1267930573.SGD","LU1778281490.HKD","LU0170899867.USD","LU1923623000.USD","LU1934455277.USD","LU2112291526.USD","SG9999002224.SGD","AWAY","IE00BJTD4N35.SGD","IE0034235188.USD","BK4543","LU2417539215.USD","LU1674673691.USD","IE00BWXC8680.SGD","LU2008162690.USD","LU0056508442.USD","CHPS","BK4529","LU1914381329.SGD","LU2237443895.HKD","LU0234570918.USD","SINTCmain","LU2756315318.SGD","ARTY","LU1116320737.USD","LU0496365809.HKD","LU2211815571.USD","LU0320765992.SGD","LU0345770993.USD","LU2750360641.GBP","AMDW","LU0965509283.SGD","BK4602","AIQ","LU0417517546.SGD","LU2237443465.HKD","LU1720051017.SGD","SG9999015952.SGD","LU2746668974.SGD","HYNX","LEGR","BK4534","IE00B5949003.HKD","LU0823421333.USD","SG9999002232.USD","07709","LU1261432733.SGD","BMED","LU0174119429.USD","IETC","LU2764263039.SGD","SOXY","LU0157215616.USD","LU0823411888.USD","SG9999015945.SGD","IE0034235295.USD","CHAT","BK4515","SMH","LU0251131958.USD","BK4561","AZNH","LU1861558580.USD","LU0882574139.USD","LU2471134952.CNY","LU0390134368.USD","AZN","LU0097036916.USD","LU0058720904.USD","LU2168563687.JPY","LU1951198990.SGD","LU0683600562.USD","LU2471134879.HKD","LU0077335932.USD","LU2461242641.AUD","LU2430703178.SGD","LU1066053197.SGD","BK4504","BK4139","AMDY","LU1236620834.HKD","LU0211327993.USD","FNCL","TRUF","IE00BJLML261.HKD","LU2361044865.SGD","IE000F7OJYX1.SGD","IE00BQXX3F31.USD","IE00BN8TJ469.HKD","SGXZ51526630.SGD","LU0823413587.USD","LU2237443549.SGD","LU0820561909.HKD","IE00B3T34201.USD","LU2430703095.HKD","LU0965509101.SGD","INTW","LU1585245621.USD","LU0122379950.USD","LU0820562030.AUD","LU0029864427.USD","LU1242518931.SGD","AIS","SKHYV","LU2168564222.USD","LU0792757196.USD","LU2237957902.USD","SLVR","LU0316494557.USD","LU0265550359.USD","LU1829250122.USD","SOXX","LU0215105999.USD","SG9999015986.USD","CNAV","FTXL","LU0345769128.USD","IE0009356076.USD","LU1852331112.SGD","LU0187121727.USD","IE00BQXX3C00.GBP","LU1989764748.USD","BK4548","IE00BLSP4452.SGD","INT","BK4578","BK4141","LU0234572021.USD","LU1670627923.USD","GDX","LU0868494617.USD","BK4535","BK4605","LU0149725797.USD","LU2168564149.EUR","LU2244417387.USD","LU1951200564.SGD","LU1303367103.USD","LU2430703251.USD","LU2242649171.HKD","LU1116320901.HKD","LU0256863902.USD","LU1551013425.SGD","LU2108987350.USD","LU2462157665.USD","IE000WAW04H5.SGD","DAMD","LU1061106388.HKD","LU2237443622.USD","SMHX","LU0127658192.USD","IE00BKVL7J92.USD","LU0128525929.USD","LU1974910355.USD","LU1150488218.USD","LU0106261372.USD","LU2764262908.HKD","IE000BZT7R73.USD","VFH","BK4232","SKHN","LU0979878070.USD","LU1934455863.HKD","TBXU","IE000SO60NU8.SGD","LU0203347892.USD","IE00BBT3K403.USD","LU0889566641.SGD","USXF","GOAU","LU1894683348.USD","SKHY","AMDU","BK4585","LU2357305700.SGD","LU0265550946.USD","LU0274383776.USD","LU2264538146.SGD","IE00BMPRXN33.USD","LU1934455194.USD","ILDR","BK4017","LU0211326755.USD","AMYY","LU1043141123.HKD","AMUU","LU0889565916.HKD","LU0432979614.USD","LU0868494708.USD","LU1803068979.SGD","LU1037948897.HKD","MEDI","IE00BHPRN162.USD","LU1988902786.USD","LU1236620750.USD","LU0823421416.USD","AMDG","LU0154236417.USD","WNDR","LU0133085943.USD","LU1043141396.HKD","IYF","SG9999015978.USD","LU1880398471.USD","IE00B775SV38.USD","SKHA","BK4567","LU0557290698.USD","LU2247934214.USD","IE00B3S45H60.SGD","BK4614","LU0965509010.AUD","LU1629891620.HKD","LU0251142724.SGD","LU2265009873.SGD","LU0256863811.USD","LU0082616367.USD","JPMO","SKHU","LU2750360997.AUD","FMTL","BAI","INTC","IYG","LU0642271901.SGD","LU1267930813.SGD","LU2764263203.CNY","BK4583","LU2361044949.HKD","LINT","LU0345774391.USD","IE00B19Z3B42.SGD","LU0114720955.EUR","SGXZ99366536.SGD","AMDL","LU2250418816.HKD","LU0640476718.USD","LU2097829019.USD","SKHL","IE00BK4W5M84.HKD","LU1057294990.SGD","LU0267386448.USD","BK4612","IE00BDCRKT87.USD","LU0708994859.HKD","SKUU","BK4554","IE0034235303.USD","KBWB","LU0048573561.USD","LU2756315664.SGD","LU2471134796.USD","LU0310800379.SGD","IE000M9KFDE8.USD","LU0654597011.USD","LU0426417589.USD","LU1363072403.SGD","TEK","IE00BJTD4V19.USD","LU2098885051.SGD","SILJ","LU0882574055.USD","HK0000304805.HKD","SK","LU2089984988.USD","SKHZ","LU2456880835.USD","LU2355687059.USD","LU1037948541.HKD","LU0787776722.HKD","LU1023059063.AUD","TTEQ","LU0109394709.USD","LU0345769631.USD","LU1430597077.USD","LU2087625088.SGD","LU1989772840.SGD","XLF","LU2896262040.SGD","INYY","IXG","HK0000304797.USD","LU2462591350.SGD","BKNU","LU0345770308.USD","LU1670628061.USD","BK4512","LU1366192091.USD","SGXZ81514606.USD","LU1150488135.SGD","LU1145028129.USD","LU0070302665.USD","LU2023250843.SGD","LU0612318385.USD","LU1861559042.SGD","LU2089985449.USD","IE00BZ1G4Q59.USD","SGXZ23171101.USD","AMD","JBHT","LU1551013342.USD","LU0943347566.SGD","LU0211328371.USD","GLDN","LU0719512351.SGD","LU0823413660.USD","LU0006306889.USD","PSI","LU0689472784.USD","FTXO","LU2468319806.SGD","LU2592432038.USD","LU0976567544.SGD","LU1244550221.USD","TMED","LU0321505868.SGD","SKHX","LU0345774631.USD","LU2720916845.USD","BK4022","LU1280957306.USD","LU2177674079.SGD","LU2236285917.USD","IE000MB6IJN5.SGD","LU2543165471.USD","LU0823397285.USD","IE00B1XK9C88.USD","IE00BK4W5L77.USD","LU1496350171.SGD","BK4516","QQQA","LU0208291251.USD","LU0081259029.USD","FNV","GILD","LU2360106780.USD","LU2360107168.USD","BK4568","LU2458330169.SGD","BK4520","WPM","LU1121112475.USD","BK4135","LU0353189680.USD","LU1668664300.SGD","LU1316542783.SGD","LU0861579265.USD","LU0994945656.USD","LU0323591593.USD","LU2746668461.USD","LU1861215975.USD","04335","LU2237443382.USD","LU0211326839.USD","LU1917777945.USD","LU2237957811.SGD","LU0786609619.USD","LU0965508806.USD","LU2361045086.USD","LU2148611432.USD","IE00B19Z3581.USD","LU2087621335.USD","IE0000B7K699.USD","LU1032466523.USD","LU2458330243.SGD","LU0251132253.USD","LU1244550494.USD","AMDD","IE00BSNM7G36.USD","WISE","TROW","BK4533","LU2168564065.EUR","LU0971096721.USD","LU2552382058.USD","LU0198837287.USD","LU0889565833.HKD","BK4579","LU2505996681.GBP","LU2168564495.EUR","XNTK","LU1571399168.USD","BK4527","LU1956131251.USD","LU0225283273.USD","LU2505996509.AUD","FAI","LU0742534661.SGD","LU1366333091.USD","LU2860962120.EUR","LU2471134523.USD","LU2213496289.HKD","LU1894683264.USD","LU2237443978.SGD","IE00BFXG1179.USD","LU1119994496.HKD","BK4550","LU1989764664.SGD","IE0002270589.USD","SAMD0main","LU0942090050.USD","LU1162221912.USD","SG9999001440.SGD","LU1720051108.HKD","AMDC","LU1880398554.USD","IE00BMPRXR70.SGD","IE00BMPRXQ63.HKD","LU0106831901.USD","LU1989772923.USD","IE00B7SZLL34.SGD","AUAU","LU2054465674.USD","LU0238689110.USD","LU1674673428.USD","LU0320765489.SGD","LU0820561818.USD","LU0310799852.SGD","TRFK","LU2552382132.HKD","LU2023250330.USD","LU2931357623.SGD","LU1496350502.SGD","BBH","JPO","BKNG","LU0289739699.SGD","LU1244550577.SGD","LU1548497426.USD","SKHQ","SG9999001424.SGD","LU2381873111.SGD","IE00BLSP4239.USD","IE0001KFT4U8.USD","IBBQ","LU1242518857.USD","LU0823416689.USD","LU1064131342.USD","LU1084165304.USD","LU1232071149.USD","LU2023250504.SGD","BK4575","IBB","LU0203345920.USD","BK4566","BK4207","LU0266013472.USD","LU1804176565.USD","LU2290526834.HKD","IE00BYXW3230.USD","LU0426412945.USD","LU0823397103.USD","IE00BDRTCR15.USD","DRIV","TFNS","BK4532","LU1066051498.USD","IE0004445239.USD","LU0321505439.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667601578","title":"AstraZeneca's Long-Term Outlook Could Look Safer After Next Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2667601578","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667601578?lang=en_us&edition=fundamental","pubTime":"2026-09-16 17:25","pubTimestamp":1789550700,"startTime":"0","endTime":"0","summary":"0925 GMT - AstraZeneca is due to report results on a number of late-stage clinical trials next year that could improve investors' confidence in its ability to continue to grow beyond 2030, analysts at J.P. Morgan say. The U.K. drugmaker has the busiest schedule of pipeline newsflow in the sector over the next 18 months, the analysts say in a research note. Two late-stage trials in breast and lung cancer are among the most highly anticipated. But AstraZeneca is also due to release data on a cholesterol pill, combinations including its diabetes, heart and kidney medicine Farxiga, and other oncology drugs, the analysts add. These trials could offer more than $10 billion in potential peak annual sales and should improve confidence in AstraZeneca's long-term outlook, according to JPM. Shares rise 0.8% to 122.10 pounds.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0310800379.SGD","LU0058720904.USD","LU2456880835.USD","LU2468319806.SGD","LU2089984988.USD","LU2237443895.HKD","LU0432979614.USD","LU1829250122.USD","LU2462157665.USD","BK4585","LU0029864427.USD","BK4007","LU2237443978.SGD","AZN","AZNH","LU2237443622.USD","LU0289739699.SGD","LU2237443465.HKD","LU0109394709.USD","IE00B3T34201.USD","LU0889565916.HKD","LU0708994859.HKD","LU0128525929.USD","LU2417539215.USD","LU2236285917.USD","LU2237443382.USD","BK4588","LU1267930573.SGD","BK4568","LU0320765992.SGD","LU2237443549.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667609445","title":"AstraZeneca Can Meet 2030 Target Even if Lung-Cancer Trial Fails","url":"https://stock-news.laohu8.com/highlight/detail?id=2667609445","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667609445?lang=en_us&edition=fundamental","pubTime":"2026-09-16 17:07","pubTimestamp":1789549620,"startTime":"0","endTime":"0","summary":"0907 GMT - AstraZeneca can meet its 2030 revenue target even if a highly anticipated lung-cancer clinical trial fails, and continue to grow thereafter, analysts at UBS say in a research note. A pullback in the U.K. drugmaker's stock after recent failures of late-stage studies and merger speculation seems overdone, according to UBS. There is some degree of uncertainty over whether AstraZeneca's lung-cancer study will lead to a clinically meaningful result, but a miss wouldn't compromise the company's $80 billion 2030 revenue target, the analysts say. The company can grow beyond 2030 despite some major drugs going off patent and still has drugs in its pipeline with potential to generate multibillion-dollar annual sales, they add. UBS cuts its target price for the stock to 152 pounds from 176 pounds. Shares rise 0.7% to 122 pounds.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0310800379.SGD","LU0058720904.USD","LU2456880835.USD","LU2468319806.SGD","LU2089984988.USD","LU2237443895.HKD","LU0432979614.USD","LU1829250122.USD","LU2462157665.USD","BK4585","LU0029864427.USD","BK4007","LU2237443978.SGD","AZN","AZNH","LU2237443622.USD","LU0289739699.SGD","LU2237443465.HKD","LU0109394709.USD","IE00B3T34201.USD","LU0889565916.HKD","LU0708994859.HKD","LU0128525929.USD","LU2417539215.USD","LU2236285917.USD","LU2237443382.USD","BK4588","LU1267930573.SGD","BK4568","LU0320765992.SGD","LU2237443549.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667062145","title":"Guardant Health Could Benefit From AstraZeneca Trial Failure, UBS Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2667062145","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667062145?lang=en_us&edition=fundamental","pubTime":"2026-09-16 03:02","pubTimestamp":1789498945,"startTime":"0","endTime":"0","summary":"Guardant Health (GH) stands to benefit from AstraZeneca's (AZN) failed Serena-4 trial because the result preserves the biomarker-driven monitoring approach supporting potential demand for its Guardant","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4196","LU2237443895.HKD","LU0058720904.USD","LU0109394709.USD","LU2237443622.USD","FFOX","LU2236285917.USD","GH","BK4585","LU0029864427.USD","LU2237443465.HKD","LU0320765992.SGD","AZNH","IE00B3T34201.USD","BK4568","LU1829250122.USD","LU2237443549.SGD","BK4588","LU0432979614.USD","LU2468319806.SGD","GNOM","LU2456880835.USD","LU2462157665.USD","LFSC","LU0310800379.SGD","LU2089984988.USD","LU2417539215.USD","AZN","LU2237443978.SGD","LU1267930573.SGD","LU0708994859.HKD","BK4551","GDOC","HELX","LU0289739699.SGD","GNMX","LU2237443382.USD","BK4007","PTH","LU0889565916.HKD","LU0128525929.USD","EKG","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667629628","title":"AstraZeneca price target lowered to 150 GBp from 160 GBp at Berenberg","url":"https://stock-news.laohu8.com/highlight/detail?id=2667629628","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667629628?lang=en_us&edition=fundamental","pubTime":"2026-09-16 01:10","pubTimestamp":1789492226,"startTime":"0","endTime":"0","summary":"Berenberg analyst Luisa Hector lowered the firm’s price target on AstraZeneca (AZN) to 150 GBp from 160 GBp and keeps a Buy rating on the shares. P...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/astrazeneca-price-target-lowered-to-150-gbp-from-160-gbp-at-berenberg-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/astrazeneca-price-target-lowered-to-150-gbp-from-160-gbp-at-berenberg-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2237443622.USD","LU0708994859.HKD","LU0128525929.USD","LU0109394709.USD","IE00B3T34201.USD","LU2237443382.USD","LU2417539215.USD","LU1829250122.USD","LU2089984988.USD","AZNH","BK4588","LU2236285917.USD","LU0320765992.SGD","LU2237443895.HKD","LU2237443465.HKD","LU2468319806.SGD","BK4007","LU2237443549.SGD","LU0432979614.USD","LU0289739699.SGD","LU1267930573.SGD","BK4568","BK4585","LU2462157665.USD","LU0889565916.HKD","LU2237443978.SGD","LU0310800379.SGD","LU0029864427.USD","LU2456880835.USD","AZN","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667649500","title":"Berenberg Trims Price Target on AstraZeneca to $203 From $214, Keeps Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2667649500","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667649500?lang=en_us&edition=fundamental","pubTime":"2026-09-15 18:42","pubTimestamp":1789468953,"startTime":"0","endTime":"0","summary":"AstraZeneca's (AZN) US stock has an average rating of buy and mean price target of $219.33, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ma","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0289739699.SGD","LU0109394709.USD","LU1267930573.SGD","AZNH","LU1829250122.USD","BK4568","LU0708994859.HKD","LU2089984988.USD","LU0889565916.HKD","LU2237443978.SGD","LU2237443895.HKD","LU2456880835.USD","LU0310800379.SGD","LU2417539215.USD","LU2237443622.USD","LU0029864427.USD","LU0128525929.USD","BK4588","LU2237443382.USD","LU0432979614.USD","AZN","LU2237443549.SGD","BK4007","LU0320765992.SGD","LU2237443465.HKD","BK4585","IE00B3T34201.USD","LU2462157665.USD","LU2468319806.SGD","LU2236285917.USD","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667964507","title":"AstraZeneca's Portfolio Diversity Bodes Well","url":"https://stock-news.laohu8.com/highlight/detail?id=2667964507","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667964507?lang=en_us&edition=fundamental","pubTime":"2026-09-15 18:07","pubTimestamp":1789466820,"startTime":"0","endTime":"0","summary":"1007 GMT - AstraZeneca has a robust and diverse portfolio, with strong opportunities in its pipeline, analysts at Berenberg say in a note. The pharmaceutical company is on track to deliver 13% return on research and development investment for its current pipeline cohort, they say. There have been some failures of highly anticipated readouts in 2026, but these were offset by other positive results, highlighting the importance of having a diverse portfolio, they add. Shares are up 2.25% at $163.78.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZN","BK4588","LU2237443382.USD","LU2468319806.SGD","LU2237443895.HKD","LU0708994859.HKD","LU2237443549.SGD","AZNH","LU0320765992.SGD","BK4007","LU2089984988.USD","LU2237443465.HKD","LU2456880835.USD","LU2236285917.USD","LU0058720904.USD","BK4585","LU1829250122.USD","LU0889565916.HKD","LU1267930573.SGD","BK4568","LU0432979614.USD","LU2237443978.SGD","LU2237443622.USD","LU0109394709.USD","LU2462157665.USD","LU0289739699.SGD","LU2417539215.USD","LU0128525929.USD","LU0310800379.SGD","LU0029864427.USD","IE00B3T34201.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667199246","title":"Berenberg Bank Remains a Buy on AstraZeneca (AZN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2667199246","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667199246?lang=en_us&edition=fundamental","pubTime":"2026-09-15 13:56","pubTimestamp":1789451762,"startTime":"0","endTime":"0","summary":"Berenberg Bank analyst Luisa Hector maintained a Buy rating on AstraZeneca yesterday and set a price target of £150.00. The company’s shares closed...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/berenberg-bank-remains-a-buy-on-astrazeneca-azn-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/berenberg-bank-remains-a-buy-on-astrazeneca-azn-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0708994859.HKD","LU2237443549.SGD","BK4007","LU2237443895.HKD","LU0058720904.USD","LU1829250122.USD","LU2468319806.SGD","LU0029864427.USD","LU2237443465.HKD","AZN","LU0128525929.USD","LU2462157665.USD","LU0320765992.SGD","LU0310800379.SGD","IE00B3T34201.USD","LU2236285917.USD","LU1267930573.SGD","LU2237443622.USD","LU0109394709.USD","LU0889565916.HKD","LU2417539215.USD","AZNH","BK4585","LU2237443978.SGD","LU2456880835.USD","LU0289739699.SGD","BK4588","LU2237443382.USD","LU2089984988.USD","BK4568","LU0432979614.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}]}}